KMT2B and adenocarcinoma: A Cox proportional hazards analysis showed that the recurrence-free survival of adenocarcinoma patients with MLL2 overexpression was approximately 1.32 (95% CI = 1.12–4.57; p = 0.01) times poorer than in patients without MLL2 overexpression after controlling for sex and pathologic stage (Table S9).